Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 crossover study of CRD-4730 in CPVT
2024-515564-32-00Phase 2Authorised
- Sponsor
- Cardurion Pharmaceuticals
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, double-blind trial of CRD-4730 in catecholaminergic polymorphic ventricular tachycardia (CPVT) (2 arms), sponsored by Cardurion Pharmaceuticals. Primary endpoint: Treatment-emergent adverse events. Planned start Nov 2025; status: authorised.
02
Drugs
CRD-4730
03
Conditions
catecholaminergic polymorphic ventricular tachycardia (CPVT)
Beyond the preview
Go deeper on 2024-515564-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515564-32-00.